Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.

ABSTRACT:

Importance

Targeted therapies have been hypothesized to prolong survival in the treatment of patients with intracranial metastatic disease (IMD) but, paradoxically, increase IMD incidence by improving systemic disease control and prolonging survival from the primary tumor. The real-world benefits of targeted therapy in treating patients with IMD are unclear, as clinical trials have excluded patients with IMD and lacked end points that report intracranial outcomes.

Objective

To assess the association of targeted therapy and IMD with patient survival.

Design, setting, and participants

This retrospective cohort study included all patients in Ontario, Canada, who received a diagnosis of IMD from April 2005 to January 2018 with primary diagnoses of breast cancer, lung or b

SUBMITTER: Erickson AW 

PROVIDER: S-EPMC8176387 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature